// App-Quantinova.ai

985 : Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Researchers

Presenter

  • Petra Muus

Principal Investigators

  • Christophe M. Legendre

  • Kenneth W. Douglas

  • Maryvonne Hourmant

  • Yahsou Delmas

  • Maria Herthelius

  • Antonella Trivelli

  • Timothy H. J. Goodship

  • Camille L. Bedrosian

  • Chantal Loirat

Medical Centers

  • Karolinska University Hospital, Stockholm, Sweden

  • Hospital for Sick Children, Toronto, ON, Canada

  • Assistance Publique -Hopitaux Paris, Hopital Robert-Debre, Paris, France

  • Beatson West Scotland Cancer Centre, Glasgow, Scotland,

  • Radboud University Medical Center, Njmegen, Netherlands

  • CHU Hotel Dieu, Nantes, France

  • Istituto Giannina Gaslini, Genoa, Italy

  • University Paris Descartes & Hopital Necker, Paris, France

  • CHU Pellegrin, Bordeaux, France

Locations

  • Canada

  • Italy

  • Netherlands

  • United Kingdom

  • France

  • Sweden

Companies

  • Alexion Pharmaceutic

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Atypical hemolytic uremic syndrome

  • Thrombotic microangiopathy

  • Hemolytic–uremic syndrome

  • Microvascular complications of diabetes 1

  • End stage renal disease

  • Chronic kidney disease

  • Renal disease

  • Hypertension

  • Albuminuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • open label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved